|
1
|
Cornice J, Capece D, Di Vito Nolfi M, Di Padova M, Compagnoni C, Verzella D, Di Francesco B, Vecchiotti D, Flati I, Tessitore A, Alesse E, Barbato G, Zazzeroni F. Ultrasound-Based Method for the Identification of Novel MicroRNA Biomarkers in Prostate Cancer. Genes (Basel) 2021; 12:genes12111726. [PMID: 34828332 PMCID: PMC8619582 DOI: 10.3390/genes12111726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 10/26/2021] [Accepted: 10/27/2021] [Indexed: 11/16/2022] Open
Abstract
The detection of circulating microRNA (miRNA)-based biomarkers represents an innovative, non-invasive method for the early detection of cancer. However, the low concentration of miRNAs released in body fluids and the difficult identification of the tumor site have limited their clinical use as effective cancer biomarkers. To evaluate if ultrasound treatment could amplify the release of extracellular cancer biomarkers, we treated a panel of prostate cancer (PCa) cell lines with an ultrasound-based prototype and profiled the release of miRNAs in the extracellular space, with the aim of identifying novel miRNA-based biomarkers that could be used for PCa diagnosis and the monitoring of tumor evolution. We provide evidence that US-mediated sonoporation amplifies the release of miRNAs from both androgen-dependent (AD) and -independent (AI) PCa cells. We identified four PCa-related miRNAs, whose levels in LNCaP and DU145 supernatants were significantly increased following ultrasound treatment: mir-629-5p, mir-374-5p, mir-194-5p, and let-7d-5p. We further analyzed a publicly available dataset of PCa, showing that the serum expression of these novel miRNAs was upregulated in PCa patients compared to controls, thus confirming their clinical relevance. Our findings highlight the potential of using ultrasound to identify novel cell-free miRNAs released from cancer cells, with the aim of developing new biomarkers with diagnostic and predictive value.
Collapse
Affiliation(s)
- Jessica Cornice
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Daria Capece
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
- Correspondence: ; Tel.: +39-0862-433560
| | - Mauro Di Vito Nolfi
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Monica Di Padova
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Chiara Compagnoni
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Daniela Verzella
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Barbara Di Francesco
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Davide Vecchiotti
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Irene Flati
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Alessandra Tessitore
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Edoardo Alesse
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| | - Gaetano Barbato
- Inno-Sol srl, Via della Ricerca Scientifica snc, ed. PP1, 00133 Rome, Italy;
- Department of Biology, School of Pharmacy, University of Rome Tor Vergata, 00133 Rome, Italy
| | - Francesca Zazzeroni
- Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, 67100 L’Aquila, Italy; (J.C.); (M.D.V.N.); (M.D.P.); (C.C.); (D.V.); (B.D.F.); (D.V.); (I.F.); (A.T.); (E.A.); (F.Z.)
| |
Collapse
|